Everyday Health16m
FDA Approves the First New Type of Schizophrenia Drug in Decades
Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...
WXXI18m
A new kind of drug for schizophrenia promises fewer side effects
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
FDA Approves First Novel Schizophrenia Drug in 70 Years, Impacting Up to 3 Million Patients in...
The FDA has approved Bristol Myers Squibb’s new schizophrenia drug, Cobenfy, the first novel treatment for schizophrenia in ...
WebMD45m
FDA Approves Revolutionary Schizophrenia Drug
In a breakthrough for people with schizophrenia, the FDA has approved a new oral medication for adults. Unlike traditional antipsychotic drugs, the medication, which will be marketed under the name ...
Des Moines Register1h
This FDA-approved drug promises a new way to treat schizophrenia
Bristol Myers Squibb will sell the drug combination under the brand name Cobenfy. The pharmaceutical company hasn't said how much it will charge for the medication. The nonprofit Institute for ...
FDA Approves Potentially Groundbreaking Schizophrenia Drug
On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...
New schizophrenia drug could 'change the lives of millions of people'
British scientists have hailed the US approval of a new drug for schizophrenia, saying it “has the potential to change the ...
New Drug For Schizophrenics Has Experts Excited
Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in decades.
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer ...
MM&M2h
Bristol Myers Squibb wins FDA approval for first new schizophrenia drug in 30 years
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.
Bristol Cobenfy approval draws optimism from Street, though with caveats
The FDA approval of Bristol Myers Squibb's Cobenfy for schizophrenia could revolutionize treatment, but faces a competitive ...